Neural and Subjective Effects of Inhaled N,N-dimethyltryptamine in Natural Settings
Overview
Authors
Affiliations
Background: N,N-dimethyltryptamine is a short-acting psychedelic tryptamine found naturally in many plants and animals. Few studies to date have addressed the neural and psychological effects of N,N-dimethyltryptamine alone, either administered intravenously or inhaled in freebase form, and none have been conducted in natural settings.
Aims: Our primary aim was to study the acute effects of inhaled N,N-dimethyltryptamine in natural settings, focusing on questions tuned to the advantages of conducting field research, including the effects of contextual factors (i.e. "set" and "setting"), the possibility of studying a comparatively large number of subjects, and the relaxed mental state of participants consuming N,N-dimethyltryptamine in familiar and comfortable settings.
Methods: We combined state-of-the-art wireless electroencephalography with psychometric questionnaires to study the neural and subjective effects of naturalistic N,N-dimethyltryptamine use in 35 healthy and experienced participants.
Results: We observed that N,N-dimethyltryptamine significantly decreased the power of alpha (8-12 Hz) oscillations throughout all scalp locations, while simultaneously increasing power of delta (1-4 Hz) and gamma (30-40 Hz) oscillations. Gamma power increases correlated with subjective reports indicative of some features of mystical-type experiences. N,N-dimethyltryptamine also increased global synchrony and metastability in the gamma band while decreasing those measures in the alpha band.
Conclusions: Our results are consistent with previous studies of psychedelic action in the human brain, while at the same time the results suggest potential electroencephalography markers of mystical-type experiences in natural settings, thus highlighting the importance of investigating these compounds in the contexts where they are naturally consumed.
Transient destabilization of whole brain dynamics induced by N,N-Dimethyltryptamine (DMT).
Piccinini J, Sanz Perl Y, Pallavicini C, Deco G, Kringelbach M, Nutt D Commun Biol. 2025; 8(1):409.
PMID: 40069397 PMC: 11897362. DOI: 10.1038/s42003-025-07576-0.
Jiwani Z, Goldberg S, Stroud J, Young J, Curtin J, Dunne J PLoS One. 2025; 20(2):e0310160.
PMID: 39937729 PMC: 11819602. DOI: 10.1371/journal.pone.0310160.
Soares C, Lima G, Pais M, Teixeira M, Cabral C, Castelo-Branco M Front Pharmacol. 2024; 15:1454628.
PMID: 39539622 PMC: 11558042. DOI: 10.3389/fphar.2024.1454628.
Bonnelle V, Feilding A, Rosas F, Nutt D, Carhart-Harris R, Timmermann C J Psychopharmacol. 2024; 38(10):887-896.
PMID: 39301949 PMC: 11512487. DOI: 10.1177/02698811241276788.
Egger K, Aicher H, Cumming P, Scheidegger M Cell Mol Life Sci. 2024; 81(1):395.
PMID: 39254764 PMC: 11387584. DOI: 10.1007/s00018-024-05353-6.